Drugs / TP04HN106
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06726577 | May 2026 → Jan 2027 expected | amyotrophic lateral sclerosis | Talengen Institute of Life Sciences, Shenzhen, P.R. China. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TP04HN106 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06726577 ↗ |
| Route | Intravenous | “received intravenous injections” NCT06726577 ↗ |